← All candidates
One insider buy in the last year — $3.00M in all.
40 filings on record.
CADLCandel Therapeutics, Inc.
NasdaqGM · Healthcare · $843.62M
$11.12
+4.17% · Sep 15
One insider buy in the last year — $3.00M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 3 sells◆ 5 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$843.62M
Float
60.2M
79% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Manning Paul B
Bought $3.00M on Feb 23 — 550,458 sh @ $5.45, held indirect, 20% of their stake.
3 of 3 positions beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
12 more transactions on Pro →Context
Wall St
$19.63 avg target
+76.5% vs today · 8 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q1 '26−$0.14 act+$0.19
Q4 '25−$0.29 act−$0.06
Q3 '25−$0.23 act−$0.06
Q2 '25−$0.20 act−$0.03
Coverage
Candel Therapeutics Designates Mark Sims as CCOExec Edge · 06-25CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is BullishStocktwits · 06-05Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer DataMarketBeat · 05-20Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
The file stays open
40 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice